Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. To elucidate novel pathways involved in erlotinib resistance, we compared the gene expression profiles...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Stanam, Aditya, Gibson-Corley, Katherine N., Love-Homan, Laurie, Ihejirika, Nnamdi, Simons, Andrean L.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342798/
https://ncbi.nlm.nih.gov/pubmed/27738319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados